BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2022 10:56:44 AM | Browse: 267 | Download: 706
 |
Received |
|
2022-04-20 20:18 |
|
Peer-Review Started |
|
2022-04-20 20:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-08 10:55 |
|
Revised |
|
2022-06-20 18:07 |
|
Second Decision |
|
2022-08-25 03:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-25 21:18 |
|
Articles in Press |
|
2022-08-25 21:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-08-22 02:22 |
|
Typeset the Manuscript |
|
2022-09-02 09:08 |
|
Publish the Manuscript Online |
|
2022-09-24 10:56 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Possible agent for COVID-19 treatment: Rifampicin
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ozlem Celik Aydin, Sonay Aydın and Sureyya Barun |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ozlem Celik Aydin, MD, Doctor, Department of Medical Pharmacology, Erzincan University, Mengucek Gazi Education and Research Hospital, Başbağlar Mahallesi Hacı Ali Akın Caddesi No. 32 Erzincan/Merkez, Erzincan 24100, Türkiye. ozlemclk_89@hotmail.com |
| Key Words |
Rifampicin; COVID-19; Treatment; In silico; Drug-drug interaction; Therapeutic potential |
| Core Tip |
Rifampicin may be used as a treatment for coronavirus disease 2019 (COVID-19). Although it has a variety of drug-drug interactions, none of the important ones for the currently utilised COVID-19 medicines, favipiravir, enoxaparin, and aspirin, have been defined. |
| Publish Date |
2022-09-24 10:56 |
| Citation |
Aydin OC, Aydın S, Barun S. Possible agent for COVID-19 treatment: Rifampicin. World J Virol 2022; 11(5): 391-393 |
| URL |
https://www.wjgnet.com/2220-3249/full/v11/i5/391.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v11.i5.391 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
